{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:10:08Z","timestamp":1768529408192,"version":"3.49.0"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T00:00:00Z","timestamp":1261094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> Although the strong association between hyperprolactinaemia and platelet aggregation is well recognized, there are no studies on changes in coagulation and fibrinolytic status in patients with prolactinoma. To our knowledge, tissue plasminogen activator inhibitor\u20101 (PAI\u20101), plasma tissue factor pathway inhibitor (TFPI) and thrombin\u2010activatable fibrinolysis inhibitor (TAFI) levels in these patients have not been investigated. Therefore, the main purpose of this study was to evaluate the markers of endogenous coagulation\/fibrinolysis, including TFPI and TAFI, and to investigate the relationships between prolactin (PRL) and these haemostatic parameters and serum lipid profile in patients with prolactinoma.<\/jats:p><jats:p><jats:bold>Research methods and procedures\u2002<\/jats:bold> Twenty\u2010two patients with untreated, newly diagnosed prolactinoma and 20 age\u2010matched healthy controls were included in the study. Platelet count, mean platelet volume, prothrombin time, activated partial thromboplastin time, fibrinogen, factors V, VII, VIII, IX and X activities, von Willebrand factor, antithrombin III (AT\u2010III), protein C, protein S, tissue plasminogen activator (t\u2010PA), PAI\u20101, TFPI and TAFI, as well as common lipid variables, were measured. The relationships between serum PRL and these haemostatic parameters were evaluated.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Compared with the control subjects, total cholesterol, low density lipoprotein cholesterol, apolipoprotein B, platelet count, fibrinogen, AT\u2010III, PAI\u20101 and PAI\u20101\/t\u2010PA ratio were significantly increased in patients with prolactinoma (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b705, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b705, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b705, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001 and <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001, respectively), whereas TFPI levels were significantly decreased (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b701). Plasma TAFI Ag levels were not significantly different in patients with prolactinoma compared with the controls. In patients with prolactinoma, serum PRL was positively correlated with plasma FVII levels and apo B (<jats:italic>r<\/jats:italic>: 0\u00b7679, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b705; <jats:italic>r<\/jats:italic>: 0\u00b7548, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b705, respectively).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> We found some important differences in the haemostatic parameters between the patients with prolactinoma and healthy controls. Increased platelet count, fibrinogen, PAI\u20101 and decreased TFPI in patients with prolactinoma may represent a potential hypercoagulable and hypofibrinolytic state, which might augment the risk for atherosclerotic and atherothrombotic complications. Thus, disturbances of the haemostatic system and dyslipidaemia may lead to the excess mortality in patients with prolactinoma.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2009.03752.x","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T14:45:09Z","timestamp":1261147509000},"page":"502-507","source":"Crossref","is-referenced-by-count":59,"title":["Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma"],"prefix":"10.1111","volume":"73","author":[{"given":"Cihangir","family":"Erem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Kocak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130rfan","family":"Nuhoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozge","family":"Ucuncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,12,18]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02469.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)59165-1"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2007.08.002"},{"key":"e_1_2_8_5_2","first-page":"101","volume-title":"Greenspan\u2019s Basic & Clinical Endocrinology: A Lange Medical Book","author":"Aron D.C.","year":"2007"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-007-0026-X"},{"key":"e_1_2_8_7_2","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1210\/jcem.86.12.8085","article-title":"PRL as a novel potent cofactor for platelet aggregation","volume":"86","author":"Wallaschofski H.","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-825727"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-814200"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-955090"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-39479"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e3281139c34"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118315"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.9.2855.009k02_2855_2859"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3422"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01484.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000063139.06585.45"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029607305580"},{"key":"e_1_2_8_19_2","first-page":"159","article-title":"The role of tissue factor pathway inhibitor in a revised coagulation cascade","volume":"29","author":"Broze G.J.","year":"1992","journal-title":"Seminars in Hematology"},{"key":"e_1_2_8_20_2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1055\/s-0038-1649880","article-title":"Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients","volume":"74","author":"Abumiya T.","year":"1995","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_21_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0038-1651668","article-title":"Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura","volume":"73","author":"Kobayashi M.","year":"1995","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<175::AID-AJH1>3.0.CO;2-X"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1490187"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041480116"},{"key":"e_1_2_8_25_2","first-page":"96","article-title":"Venous and arterial thrombophilia","volume":"82","author":"Girolami A.","year":"1997","journal-title":"Haematologica"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-924064"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.d01-1743.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90111-X"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198408233110804"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000181762.31694.da"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(03)00244-9"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200212000-00001"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1657549"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.13.10.1412"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)93050-9"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:13:1:37"},{"key":"e_1_2_8_37_2","first-page":"11","article-title":"Prolactin inhibition of FSH\u2010induced tissue type plasminogen activator expression in cultured rat granulosa cells","volume":"50","author":"Liu Y.X.","year":"1998","journal-title":"Sheng Li Xue Bao"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2007.12.001"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1871"},{"key":"e_1_2_8_40_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1160\/TH05-06-0412","article-title":"Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism","volume":"94","author":"Hoke M.","year":"2005","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1159\/000083833"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.24.14477"},{"key":"e_1_2_8_43_2","first-page":"184","article-title":"Interrelationship between TSH\u2010 and prolactin secretion in patients with prolactinoma and autoimmune thyroiditis","volume":"100","author":"Pelkonen R.","year":"1982","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01721038"},{"key":"e_1_2_8_45_2","first-page":"312","article-title":"Decreased apolipoprotein levels in women with hyperprolactinemia related to increased estradiol level: effect of hepatic lesion?","volume":"19","author":"Oravec S.","year":"1985","journal-title":"Endocrinologia Experimentalis"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/14.2.285"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2009.03752.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2009.03752.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T13:18:59Z","timestamp":1698758339000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2009.03752.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,18]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1365-2265.2009.03752.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03752.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,18]]}}}